{Reference Type}: Journal Article
{Title}: Prophylactic sildenafil to prevent bronchopulmonary dysplasia: A systematic review and meta-analysis.
{Author}: Hirata K;Nakahari A;Takeoka M;Watanabe M;Nishimura Y;Katayama Y;Isayama T; ;
{Journal}: Pediatr Int
{Volume}: 66
{Issue}: 1
{Year}: 2024 Jan-Dec
{Factor}: 1.617
{DOI}: 10.1111/ped.15749
{Abstract}: <B>BACKGROUND: </B>Bronchopulmonary dysplasia (BPD) persists as one of the foremost factors contributing to mortality and morbidity in extremely preterm infants. The effectiveness of administering sildenafil early on to prevent BPD remains uncertain. The aim of this study was to investigate the efficacy and safety of prophylactically administered sildenafil during the early life stages of preterm infants to prevent mortality and BPD.<BR><B>METHODS: </B>MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, and Ichushi were searched. Published randomized controlled trials (RCTs), non-RCTs, interrupted time series, cohort studies, case-control studies, and controlled before-and-after studies were included. Two reviewers independently screened the title, abstract, and full text, extracted data, assessed the risk of bias, and evaluated the certainty of evidence (CoE) following the Grading of Recommendations Assessment and Development and Evaluation approach. The random-effects model was used for a meta-analysis of RCTs.<BR><B>RESULTS: </B>This review included three RCTs (162 infants). There were no significant differences between the prophylactic sildenafil and placebo groups in mortality (risk ratio [RR]: 1.32; 95% confidence interval [CI]: 0.16-10.75; very low CoE), BPD (RR: 1.20; 95% CI: 0.79-1.83; very low CoE), and all other outcome assessed (all with very low CoE). The sample sizes were less than the optimal sizes for all outcomes assessed, indicating the need for further trials.<BR><B>CONCLUSIONS: </B>The prophylactic use of sildenafil in individuals at risk of BPD did not indicate any advantageous effects in terms of mortality, BPD, and other outcomes, or increased side effects.